Let's Make a Deal: Levin's Ovid Raises $75m
This article was originally published in Scrip
Executive Summary
Former Teva Pharmaceutical Industries president and CEO Jeremy Levin has gone back to his dealmaking roots as chairman and CEO of Ovid Therapeutics, which just closed a $75m Series B funding round to fund development and acquisition of treatments for rare neurological diseases.